Placebo + CB-839 + everolimus
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clear Cell Renal Cell Carcinoma
Conditions
Clear Cell Renal Cell Carcinoma
Trial Timeline
Sep 6, 2017 → Jun 1, 2020
NCT ID
NCT03163667About Placebo + CB-839 + everolimus
Placebo + CB-839 + everolimus is a phase 2 stage product being developed by Calithera Biosciences for Clear Cell Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03163667. Target conditions include Clear Cell Renal Cell Carcinoma.
What happened to similar drugs?
3 of 13 similar drugs in Clear Cell Renal Cell Carcinoma were approved
Approved (3) Terminated (1) Active (9)
✅nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)Sumitomo PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03163667 | Phase 2 | Completed |
Competing Products
20 competing products in Clear Cell Renal Cell Carcinoma